Earn CME Credit: https://www.naccme.com/program/7327
Knowledge is evolving regarding numerous clinical aspects of immune thrombocytopenic purpura (ITP), and there remains significant variability in clinical practice patterns for its management. This activity features Drs. David P. Steensma and Ilene C. Weitz sharing their insights about data recently released in publication form pertaining to pharmacotherapy for ITP, with a focus on the use of thrombopoietin (TPO) receptor agonists.
© 2019 Imedex, an HMP Company